What happened in this episode?
Peter Attia speaks with maternal–fetal medicine specialist Katie (MD–PhD) about pregnancy as a whole-body physiologic “stress test” and what it can reveal about long-term maternal health. They cover early pregnancy hormonal transitions from ovarian support to placental hormone production, and discuss severe nausea and vomiting (hyperemesis gravidarum), with the guest pointing to genetic evidence implicating GDF-15 as a potential therapeutic target.
The conversation devotes substantial time to cardiometabolic adaptation, including plasma volume expansion and insulin resistance. Katie outlines how gestational diabetes is screened (typically 24–28 weeks), why insulin is often first-line when diet changes fail, and says roughly half of gestational diabetes patients later develop type 2 diabetes, making postpartum surveillance important.
On hypertensive disorders, she defines preeclampsia and describes a mechanistic model in which placental hypoxia triggers release of the anti-angiogenic factor sFlt-1, affecting maternal endothelium and kidney function. She says postpartum hypertension can persist for weeks, and argues obstetric history is often missed in primary care despite its predictive value; she also notes genetic overlap between preeclampsia and essential hypertension.
They also discuss caesarean section trends and indications, the limitations of explaining stillbirth (which she says occurs about once per 160 pregnancies after 20 weeks), and advances in non-invasive prenatal screening via cell-free DNA. The episode ends with policy and research concerns, including insurance gaps in US postpartum care and underinvestment in pregnancy research at the NIH.
